pharmaphorum

Vertex buys diabetes cell therapy rival ViaCyte for $320m

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has been ...
The Motley Fool

Where Will Vertex Pharmaceuticals Be in 5 Years

Some things will remain the same for Vertex five years from now, including its dominance in treating cystic fibrosis (CF). However, the company will likely achieve success in several new markets ...
The Boston Globe

Vertex’s CEO was an AI skeptic. But not anymore.

Robots may not be taking the place of researchers in lab coats running clinical trials anytime soon, but AI is playing an increasingly important role in drug discovery efforts. That’s the message ...
FiercePharma

Vertex touts Journavx launch metrics after novel pain med came up just short of expectations in Q3

During Vertex’s third-quarter presentation, Chief Commercial Officer Duncan McKechnie cited several numbers that suggest the launch of its long-awaited, non-opioid pain reliever Journavx is trending ...
Yahoo Finance

Vertex Pharmaceuticals (VRTX) Q3 Earnings: What To Expect

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be announcing earnings results this Monday after market hours. Here’s what you need to know. Vertex Pharmaceuticals beat analysts’ revenue ...
Investopedia

Vertex Pharmaceutical Stock Dives as Firm to Stop Developing Acute Pain Drug

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...
FiercePharma

Vertex narrows near-term development plan for Journavx after FDA naysays broad label in neuropathic pain

After the FDA's landmark approval of the opioid-free acute pain reliever Journavx in January, Vertex Pharmaceuticals has hit a snag on its path to expand the potential blockbuster’s reach into ...
Seeking Alpha

Vertex Pharmaceuticals stock falls as pain drug fails in phase 2

Vertex Pharmaceuticals (NASDAQ:VRTX) shares fell in premarket trading on Tuesday after the company's VX-993 failed to meet the primary endpoint in the Phase 2 pain study, offsetting a strong quarterly ...
BioSpace

Trial Failure of Vertex’s Next-Gen Pain Drug Mars Strong Q2 Earnings

Vertex reported healthy revenue in its second quarter earnings report, though news of VX-993’s mid-stage trial results and lack of alignment with the FDA regarding an expanded label for Journavx ...
Reuters

Vertex's trial failure, scrapped study cloud pain drug push; shares slump

Aug 4 (Reuters) - Vertex Pharmaceuticals will stop developing its experimental non-opioid painkiller as a solo treatment after a mid-stage trial failure and will not start a study for expanded use of ...
The Boston Globe

Vertex next-generation pain candidate fails Phase 2 trial

This story is republished from STAT, the health and medicine news site that’s a partner to the Globe. Sign up for STAT’s free Morning Rounds newsletter here. Vertex Pharmaceuticals said Monday that ...
Yahoo Finance

Vertex Down Around 9% in Three Months: Should You Buy, Sell or Hold the Stock?

Vertex Pharmaceuticals Incorporated VRTX stock has declined 8.9% in the past three months. The deterioration was due to soft first-quarter results, slower-than-expected uptake of its newer drugs as ...